GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Appili Therapeutics Inc (OTCPK:APLIF) » Definitions » Notes Receivable

APLIF (Appili Therapeutics) Notes Receivable : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Appili Therapeutics Notes Receivable?

Appili Therapeutics's Notes Receivable for the quarter that ended in Jun. 2024 was $0.00 Mil.


Appili Therapeutics Notes Receivable Historical Data

The historical data trend for Appili Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Appili Therapeutics Notes Receivable Chart

Appili Therapeutics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Appili Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Appili Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Appili Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Appili Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Appili Therapeutics Business Description

Traded in Other Exchanges
Address
1344 Summer Street, Suite 21, Halifax, NS, CAN, B3H 0A8
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Appili Therapeutics Headlines

From GuruFocus

Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA

By Business Wire Business Wire 02-08-2023

Appili Therapeutics -- Press Release Correction

By Business Wire 06-23-2023